ix. Figure legends
FIGURE 1. Patient flow through the study.
FIGURE 2. Levels of sIgE concentrations for nut-specific storage proteins Ana o3 / Ara h2 for cashew nut and peanut
allergic patients undergoing OIT. Values >100 kU/L were set to 120 kU/L.
FIGURE 3. A Severity of allergic reactions during OIT by nut allergy graded by oFASS-5.
B Severity of side effects during OIT by nut allergy and separated by presence of other food allergies.C Heatmap of the severity of reaction during OIT (mild: oFASS 0-1; moderate: oFASS 2-3; severe: oFASS 4-5) in relation to the initial levels of sIgE against storage proteins (Ana o3, Ara h2).
FIGURE 4. Cumulative incidence curves for reaching maintenance dose in patients (A) undergoing therapy in the cashew nut (N=24) and the peanut (N=38) group, (B) with (N=31) and without asthma (N=31), (C) with (N=33) and without (N=29) other food allergy, 1) representing the patients who reached the maintenance dose (continuous lines), 2) the group of patients who were defined as drop-outs (n=11) (dashed lines). Dotted line represents median time to reaching maintenance dose.
FIGURE 5. A Changes of sIgE for the storage protein (Ana o3/Ara h2) from t0 (=before starting the OIT) to t1 (=reaching maintenance dose). Available data for cashew nut (n=19) and peanut (n=25).
B Progression over time of sIgE’s for the storage protein (Ana o3/Ara h2) for the patients who underwent a second OFC (t2) for cashew nut (n=8) and peanut (n=13). Black lines are representing patients who had no reaction during the second OFC and were classified as desensitized, red lines representing patients who failed to complete the second OFC with an intolerance.
x. Appendices
Supplementary material on OIT starting protocol